Incyte Reports 2019 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Incyte (INCY) PT Raised to $98 at Mizuho Securities
October 30, 2019 8:03 AM EDTMizuho Securities analyst Mara Goldstein raised the price target on Incyte (NASDAQ: INCY) to $98.00 (from $95.00) while maintaining a Buy rating.
The analyst commented, "We continue to like INCY based on the combination of cash flow generated by JAKAFI and opportunities from potential... More
Incyte (INCY) Tops Q3 EPS by 17c, Revenues Beat; Raises FY19 Jakafi Revenue Outlook
October 29, 2019 7:12 AM EDTIncyte (NASDAQ: INCY) reported Q3 EPS of $0.82, $0.17 better than the analyst estimate of $0.65. Revenue for the quarter came in at $551.58 million versus the consensus estimate of $534.88 million.
Total product and royalty revenues of $534 million (+24% vs. Q3 2018) and Jakafi® (ruxolitinib) revenues of $433 million (+25% vs. Q3 2018) for the quarter ended September 30, 2019;... More